Actively Recruiting
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Led by Ying Lin · Updated on 2023-03-09
66
Participants Needed
1
Research Sites
347 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.
CONDITIONS
Official Title
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed Her-2 negative breast cancer
- TNM stage: T1c with N1-N2; T2-4 with N0-N2; or any T with N3
- No distant metastatic disease
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Presence of at least one pathogenic or likely pathogenic HRR gene mutation in germline or somatic BRCA1, BRCA2, PALB2, ATM, BARD1, BRIP1, CDK12, CHEK2, RAD51C, or RAD51D genes
You will not qualify if you...
- Pregnant or breastfeeding women or those unwilling to use contraception
- History of other malignant diseases within the past 2 years, except cured skin basal cell carcinoma, breast carcinoma in situ, or cervical carcinoma in situ
- Psychiatric disorders, peripheral or central nervous system diseases, or any condition affecting ability to consent or participate
- History of myocardial infarction, congestive heart failure, or other serious heart diseases
- Use of immunosuppressive drugs or corticosteroids within 14 days prior to enrollment
- Any other diseases as determined by the researchers
- Allergy to any of the study drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
Y
Ying Lin, MD
CONTACT
X
Xiaying Kuang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here